LEADER 04104nam  2201081z- 450 
001 9910557512703321
005 20220111
035   $a(CKB)5400000000044428
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/77048
035   $a(oapen)doab77048
035   $a(EXLCZ)995400000000044428
100   $a20202201d2021      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aRadiolabeled Compounds for Diagnosis and Treatment of Cancer
210   $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021
215   $a1 online resource (262 p.)
311 08$a3-0365-2427-4 
311 08$a3-0365-2426-6 
330   $aRadiopharmaceuticals are used in the diagnosis and treatment of various diseases, especially cancer. In general, radiopharmaceuticals are either salts of radionuclides or radionuclides bound to biologically active molecules, drugs, or cells. Tremendous progress has been made in discovering, developing, and commercializing numerous radiopharmaceuticals for the imaging and therapy of cancer. Significant research is ongoing in academia and the pharmaceutical industry to develop more novel radiolabeled compounds as potential radiopharmaceuticals for unmet needs. This Special Issue aims to focus on all aspects of the design, characterization, evaluation, and development of novel radiolabeled compounds for the diagnosis and treatment of cancer and the application of new radiochemistry and methodologies for the development of novel radiolabeled compounds. Outstanding contributions presented in this Special Issue will significantly add to the field of radiopharmaceuticals.
606   $aChemistry$2bicssc
606   $aResearch and information: general$2bicssc
610   $a123,124,125,131I-labeled molecules and biomolecules
610   $a124I-labeled monoclonal antibodies
610   $a188Re-liposome
610   $aAAZTA
610   $aadrenergic receptor
610   $aaprepitant
610   $abiomolecules
610   $abreast
610   $acancer
610   $acancer imaging and therapy
610   $acholecystokinin-2 receptor
610   $acleavable linkers
610   $aDPP
610   $aEpCAM
610   $aFAP
610   $afluorine-18
610   $ahypopharyngeal cancer
610   $aimaging
610   $aimaging pharmaceuticals
610   $aimmunoPET imaging pharmaceuticals
610   $aiodine
610   $akidney uptake
610   $alutetium-177
610   $amicroRNA
610   $aminigastrin
610   $amolecular imaging
610   $amonoclonal antibodies
610   $an/a
610   $aneurokinin 1 receptor antagonist
610   $aneutral endopeptidase (NEP)
610   $aNGS
610   $apeptides
610   $aPET
610   $aPET probes
610   $aPIB
610   $apositron emission tomography
610   $apositron emission tomography (PET)
610   $aPREP
610   $aproduction processes
610   $aprostate-specific membrane antigen (PSMA)
610   $aproteins
610   $apyrazoles
610   $aradioiodination
610   $aradioiodine labeling
610   $aradiolabeling
610   $aradionuclide
610   $aradionuclide chelators
610   $aradionuclide therapy
610   $aradionuclides
610   $aradiopharmaceuticals
610   $aradiotracer
610   $aradiotracers
610   $arenal brush border enzymes
610   $arepeated therapy
610   $aSA
610   $ascandium-44
610   $asomatostatin analogs
610   $aSPECT
610   $atarget-specific biomolecules
610   $atargeted radiotherapy
615  7$aChemistry
615  7$aResearch and information: general
700   $aKumar$b Krishan$4edt$0125816
702   $aKumar$b Krishan$4oth
906   $aBOOK
912   $a9910557512703321
996   $aRadiolabeled Compounds for Diagnosis and Treatment of Cancer$93030930
997   $aUNINA